Exchange: NASDAQ·Updated 07:30 PM EST
DNLI logo

DNLI Denali Therapeutics Inc

$18.08
$0.66
(3.52%)
Today
Closed $18.08
$0.00
(0.00%)
After Hours
Reported EarningsNov 3
Mkt Cap$3B
Vol1.15M

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
53

Neutral Sentiment

How do you feel about DNLI?

Advertisement|Remove ads.